在绝经后的骨质疏松症中,登诺苏马布和特里帕蒂德的过渡 (DATA-Switch研究):随机对照试验的延伸
Benjamin Z Leder1, Joy N Tsai1, Alexander V Uihlein1
1Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, MA, USA.
Lancet (London, England)
|July 7, 2015
概括
将骨质疏松症患者从teriparatide转换为denosumab维持了骨矿物质密度的增加. 相反,从德诺苏马布转换为特里巴化物导致骨质损失,影响骨质疏松症的治疗策略.
科学领域:
- 内分泌学 在内分泌学.
- 骨生物学 骨生物学 骨生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨质疏松症的治疗通常涉及单一药物,在恢复骨完整性方面有效性有限.
- 连续使用药物很常见,但最佳的转换策略仍然不清楚.
- 之前的研究表明,结合的特里巴和德诺苏马布可以提高骨矿物质密度 (BMD).
研究的目的:
- 为了评估在teriparatide和denosumab疗法之间过渡的绝经后骨质疏松症妇女的BMD变化.
- 为了比较不同药物切换序列在骨密度和营业额标志物的疗效.
主要方法:
- 一个随机对照试验 (DATA-Switch) 扩展了数据研究.
- 94名绝经后的妇女接受了24个月的特里帕蒂德,德诺苏马布或两者.
- 然后,参与者转向单独使用登苏玛布,单独使用特里巴或继续使用登苏玛布,并在48个月内测量 BMD.
主要成果:
- 从teriparatide切换到denosumab保持了BMD的增加.
- 从德诺苏马布转换为特里巴化物导致渐进或短暂的骨质损失.
- 组合疗法组显示,部和大腿部部总体BMD的增加最大.
结论:
- 从teriparatide切换到denosumab是有效的维护BMD.
- 从德诺苏马布转换为特里巴拉提德可能会导致骨质损失,需要仔细规划治疗.
- 治疗顺序显著影响绝经后骨质疏松症的骨密度结果.
相关概念视频
01:40Bone Remodeling
41.1K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
41.1K
01:31Osteoclasts in Bone Remodeling
4.8K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.8K
01:29Bone Disorders
8.1K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
8.1K
01:17Hormones and Bone Tissue
4.2K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
4.2K
01:28Menopause
5.2K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
5.2K
01:18Transdermal Drug Delivery Systems
157
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
157